Myelodysplastic Syndromes (MDS): Classification, Prognosis, and Therapy

MDS are clonal hematopoietic stem cell disorders with dysplasia, cytopenias, and risk of AML transformation. Median age 70; incidence ~4/100,000.

WHO 2022 / ICC Classification Highlights

  • Defined by cytopenias + dysplasia (≥10% in lineage) + cytogenetics/molecular.
  • Key subtypes: MDS with low blasts (MDS-LB), MDS with increased blasts (MDS-IB1/2), MDS with SF3B1 mutation (ring sideroblasts), MDS with isolated del(5q), MDS/MPN overlap.
  • TP53 mutation (multi-hit) = distinct aggressive entity.

Prognostic Scoring

  • IPSS-R (Revised): Cytogenetics, blast %, cytopenias → 5 risk groups (Very Low → Very High). Median OS: 8.8 yr (VL) to 0.8 yr (VH).
  • IPSS-M (Molecular): Adds mutations (TP53, FLT3, RAS, SF3B1, etc.) — more precise.
  • Molecular IPSS (IPSS-M) now preferred for treatment decisions.

Treatment by Risk

RiskApproach
Lower (IPSS-R VL/Low; IPSS-M VL/Low)Supportive: ESA (epoetin) for anemia; G-CSF for infections; transfusions (RBC/platelets); iron chelation if ferritin >1000. Luspatercept (erythroid maturation agent) for ring sideroblast+ MDS post-ESA.
Higher (Int/High/VH)Hypomethylating agents (HMA): Azacitidine (SC/IV q28d) or Decitabine (IV q28d). Goal: delay AML, improve survival. Venetoclax + HMA (emerging). Allo-HSCT only curative — refer early (age/fitness permitting).
del(5q) isolatedLenalidomide (transfusion independence ~67%).

Supportive Care Essentials

  • Transfusion thresholds individualized; pathogen-reduced/irradiated products.
  • Infection prophylaxis (PJP if on HMA/immunosuppressed).
  • Vaccinations (non-live); advance care planning.

Monitoring

CBC every 1–3 months; marrow every 6–12 months or at progression; molecular tracking (VAF trends).

Genetic Disorders - Related Articles